Inhibiting Src-mediated PARP1 tyrosine phosphorylation confers synthetic lethality to PARP1 inhibition in HCC-Reference-Cited by-同舟云学术

Inhibiting Src-mediated PARP1 tyrosine phosphorylation confers synthetic lethality to PARP1 inhibition in HCC

Published:2022-02 Issue: Volume:526 Page:180-192
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Sun Caiyu,Jing Weiqiang,Xiong Gaozhong,Ma Dapeng,Lin Yueke,Lv Xiaoting,Zhao Yunxue,Ma Xiaomin,Zhu Lihui,Shen Xuecheng,Yang Min,Qin Zhenzhi,Cheng Yeping,Xuan Haocheng,Li Tao,Han Lihui^ORCID

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference46 articles.

1. Hepatocellular carcinoma;Villanueva;N. Engl. J. Med.,2019

2. Enhancement of poly-adenosine diphosphate-ribosylation in human hepatocellular carcinoma;Nomura;J. Gastroenterol. Hepatol.,2000

3. Expression of poly(ADP-ribose) polymerase in human hepatocellular carcinoma and analysis of biopsy specimens obtained under sonographic guidance;Shimizu;Oncol. Rep.,2004

4. Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma;Gabrielson;Cancer Chemother. Pharmacol.,2015

5. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design;Llovet;Clin. Cancer Res.,2014

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PINX1 loss confers susceptibility to PARP inhibition in pan-cancer cells;Cell Death & Disease;2024-08-22

2. HBXIP induces PARP1 via WTAP-mediated m6A modification and CEBPA-activated transcription in cisplatin resistance to hepatoma;Acta Pharmacologica Sinica;2024-06-13

3. SKP2 promotes the metastasis of pancreatic ductal adenocarcinoma by suppressing TRIM21-mediated PSPC1 degradation;Cancer Letters;2024-04

4. Polo-like kinase 4 promotes tumorigenesis and glucose metabolism in glioma by activating AKT1 signaling;Cancer Letters;2024-03

5. The biological essence of synthetic lethality: Bringing new opportunities for cancer therapy;MedComm – Oncology;2024-03